| Stereochemistry | ABSOLUTE |
| Molecular Formula | C27H35NO5 |
| Molecular Weight | 453.5705 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 7 / 7 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC[C@@](C)(O)[C@H]1C[C@@]23C=C[C@]1(OC)[C@@H]4OC5=C(OC(C)=O)C=CC6=C5[C@]24CCN(C)[C@@H]3C6
InChI
InChIKey=LFYBMMHFJIAKFE-PMEKXCSPSA-N
InChI=1S/C27H35NO5/c1-6-9-24(3,30)19-15-25-10-11-27(19,31-5)23-26(25)12-13-28(4)20(25)14-17-7-8-18(32-16(2)29)22(33-23)21(17)26/h7-8,10-11,19-20,23,30H,6,9,12-15H2,1-5H3/t19-,20-,23-,24-,25-,26+,27-/m1/s1
Acetorphine is a synthetic narcotic analgesic. Acetorphine was reported to have uses in veterinary medicine with pronounced advantages in the immobilization of the giraffe in which toxic effects were reduced as compared to the effects of etorphine. In July 1966, the Director-General of the World Health Organization informed the Secretary-General that WHO had arrived at the conclusion that etorphine and acetorphine should be included in Schedule I of the Convention, since they could give rise to similar abuse, and produce similar ill effects as the substances already listed therein. Acetorphine is a Schedule I controlled substance in the United States.
Approval Year
PubMed
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
